Welcome to our dedicated page for ALLURION TECHNOLOGIES SEC filings (Ticker: ALUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allurion Technologies, Inc. (NYSE: ALUR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Allurion’s medical device business focused on metabolically healthy weight loss, its Allurion Program, and the Allurion Smart Capsule, which the company describes as a swallowable, Procedureless™ gastric balloon for weight loss and an investigational device in the United States.
Through periodic reports and current reports on Form 8-K, Allurion outlines financial results, capital structure changes, and governance matters. Filings referenced in recent disclosures include notifications of late filing on Form 12b-25, restatements related to accounting for a revenue interest financing agreement and convertible senior secured notes, and descriptions of material weaknesses in internal control over financial reporting. Investors can review these filings to understand how non-cash accounting adjustments affect items such as Other Comprehensive Income (Loss) and Other Income (Expense), as well as the company’s commentary that these corrections are not expected to impact revenue, gross margin, operating expenses, or cash.
Allurion’s SEC filings also describe capital markets and financing transactions, such as a private placement of common stock and accompanying warrants, and an exchange agreement to convert outstanding debt and obligations under revenue interest financing agreements into shares of Series B convertible preferred stock, subject to stockholder approval and exchange listing requirements. Definitive proxy materials provide further detail on proposals for stockholders, including amendments to stock plans, option repricing, preferred share and warrant share issuances, and a potential reverse stock split within an approved ratio range.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the key points of complex documents like 10-Ks, 10-Qs, 8-Ks, and proxy statements in plain language. Users can quickly see the main themes in Allurion’s disclosures on regulatory progress for the Allurion Smart Capsule, financial performance, risk factors, and governance decisions, while still having access to the full original SEC documents for deeper analysis.
Allurion Technologies, Inc. (ALUR)RTW Investments, LP acquired common stock and accompanying warrants in a private placement. The reporting entities bought blocks of 991,544, 767,848 and 96,896 shares of common stock, each with matching warrants, at a purchase price of $1.67 per share and accompanying warrant. Following these transactions, the funds report beneficial ownership of up to 3,138,798, 2,427,089 and 298,992 shares through different RTW-managed vehicles, plus an additional 26,551 shares in another fund. The warrants carry an exercise price of $1.67 per share, become exercisable only after stockholder approval, and expire five years after that approval. Each warrant is subject to a beneficial ownership cap of 4.99% (or 9.99% at the holder’s election), and Allurion has agreed to use its reasonable best efforts to hold a stockholder meeting no later than January 31, 2026 to seek approval for the warrant share issuance.
Allurion Technologies (ALUR): RTW Investments and affiliates filed an amended Schedule 13D disclosing 48.1% beneficial ownership, or 5,891,430 shares, based on 12,249,232 shares outstanding upon the private placement closing.
On November 11, 2025, RTW agreed to exchange remaining note principal, $48.0 million under a 2023 revenue interest financing agreement and $9.5 million under a 2024 agreement for Series B convertible preferred stock. The preferred has an 8.25% dividend, is convertible at $3.37 per share of common stock, and includes a 9.9% beneficial ownership conversion cap. Closing is subject to stockholder approval and listing/effectiveness conditions.
RTW funds also bought 1,856,288 shares with accompanying warrants at $1.67 per unit for approximately $3.1 million. Governance terms allow RTW to nominate one or two directors while it holds at least 10% or 30% of the Company’s securities, respectively, with additional nomination rights upon a specified breach tied to a $3.0 million minimum cash balance and FDA marketing authorization by December 31, 2026.
Allurion Technologies, Inc. has an effective prospectus covering the resale of up to 65,211,325 shares of common stock, and this supplement adds details from a new current report. The company agreed to a $5 million private placement of 2,994,012 common shares and accompanying warrants at $1.67 per share and warrant, with the warrants exercisable after stockholder approval of the underlying shares, which the company must seek by January 31, 2026.
Allurion also signed an exchange agreement with RTW to swap all amounts outstanding under certain convertible notes and two revenue interest financing agreements for newly created Series B convertible preferred stock with a stated value of
Allurion Technologies (ALUR) announced two financing moves. The company agreed to a private placement of 2,994,012 common shares with accompanying warrants to purchase up to 2,994,012 shares, for an aggregate purchase price of about $5 million at $1.67 per share and warrant. The warrants are exercisable after stockholder approval at an exercise price of $1.67 and expire five years after approval, with a beneficial ownership cap of 4.99% (or 9.99% at the holder’s election). A resale registration is targeted to be filed by January 10, 2026; Roth Capital Partners will receive a 7% cash fee on gross proceeds and up to $100,000 in expenses.
Separately, Allurion agreed with RTW to exchange its outstanding notes and obligations under two revenue interest financing agreements for newly created Series B convertible preferred stock, subject to stockholder approval no later than January 31, 2026. Each preferred share has a $1,000 stated value, accrues 8.25% dividends, and is convertible at $3.37 per share (subject to adjustment) with a 9.9% beneficial ownership limit. In a related step, on November 4–5, 2025, RTW converted approximately $5 million of notes at the floor conversion price of $3.35, receiving 1,492,539 common shares.
Allurion Technologies (ALUR): RTW files Amendment No. 9 to Schedule 13D, reporting beneficial ownership of 4,035,142 shares, or 43.6% of the common stock.
On November 5, 2025, the RTW funds converted $5.0 million principal amount of notes into 1,492,539 shares under an amended note purchase agreement. The ownership percentages are based on 7,762,681 shares outstanding as of August 8, 2025, plus the shares issued pursuant to the November 2025 conversion notice. RTW Investments, LP and Roderick Wong report shared voting and dispositive power over 4,035,142 shares.
By entity, RTW Master Fund, Ltd. reports 2,147,254 shares (23.2%), and RTW Innovation Master Fund, Ltd. reports 1,659,241 shares (17.9%). The notes include a 9.99% beneficial ownership conversion cap, while RTW’s warrants are subject to a 4.99% blocker that can be increased to 9.99% with 61 days’ prior notice.
Allurion Technologies (ALUR): Affiliated funds managed by RTW Investments reported converting an aggregate $5.0 million principal amount of Allurion’s convertible senior secured notes into common stock at the floor conversion price of $3.35 per share on November 5, 2025. The filing identifies the reporting persons as a Director and 10% owner and indicates the form is filed by more than one reporting person.
The conversion resulted in share issuances to multiple RTW-managed entities, including 822,722 shares to RTW Master Fund and 631,954 shares to RTW Innovation. The notes bear 6.0% annual interest and mature on April 16, 2031. Remaining notes are convertible at $40.50 per share and may also be converted at additional prices at the issuer’s discretion. A 9.99% beneficial ownership limitation applies, unless a discretionary conversion is used.
Allurion Technologies amended its quarterly report to reflect a restatement and adjustments tied to a Reverse Stock Split and the closing of its Business Combination with Compute Health. The filing discloses material weaknesses in internal control over financial reporting and describes remediation steps including hiring accounting staff, implementing a new ERP, and engaging a national accounting firm.
The company completed several financing and capital transactions: a PIPE investment of $37.9 million, a Public Offering consummated July 1, 2024, amended convertible note arrangements, and revenue interest financing that pays 6.0% of annual net sales through 2026 and up to 10.0% thereafter until 2030. The Allurion Balloon sales were suspended in France and remediation is underway; the company also disclosed NYSE non-compliance and submitted a plan to regain compliance.
Allurion Technologies amended its Form 10-Q to restate prior interim financials and reflect a 1-for-25 reverse stock split effective January 3, 2025. The filing discusses the completed Business Combination with Compute Health and conversion/recapitalization mechanics that produced Allurion common stock and warrants, notes the Company completed a Public Offering on July 1, 2024, and records a $37.9 million PIPE investment. The company discloses material weaknesses in internal control over financial reporting and remediation actions underway, and reports a suspension of Allurion Balloon sales in France in August 2024. Debt and convertible note amendments, warrant conversions and derivative accounting for certain PIPE and conversion options are described.
Allurion Technologies, Inc. amended its quarterly report to reflect a reverse stock split and provides details on the previously completed Business Combination with Compute Health Acquisition Corp., related equity recapitalizations, and follow-on financing arrangements. The filing discloses a $37.9 million PIPE investment and multiple convertible note, term loan and revenue-interest financing arrangements with detailed conversion, royalty and reset provisions that could affect future dilution and cash obligations.
The company disclosed prior-period adjustments related to retroactive share restatements from the Business Combination, and identified material weaknesses in internal control over financial reporting with described remedial steps including hiring accounting staff, implementing a new ERP, additional review controls, and engagement of a national accounting firm. The filing also discusses contingent consideration valuation, warrant liabilities, and various debt modifications and covenant features.
FAQ
What is the current stock price of ALLURION TECHNOLOGIES (ALUR)?
What is the market cap of ALLURION TECHNOLOGIES (ALUR)?
